Take Ltd
Incorporated in 2000, TAKE Solutions Ltd is in the business of Life Sciences and Support Services[1]
- Market Cap ₹ 204 Cr.
- Current Price ₹ 13.8
- High / Low ₹ 50.1 / 10.1
- Stock P/E 34.6
- Book Value ₹ 2.10
- Dividend Yield 0.00 %
- ROCE 18.5 %
- ROE 16.5 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
Cons
- Stock is trading at 6.59 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -41.2% over past five years.
- Tax rate seems low
- Company has a low return on equity of -47.0% over last 3 years.
- Contingent liabilities of Rs.74.5 Cr.
- Earnings include an other income of Rs.14.9 Cr.
- Working capital days have increased from -2,718 days to 123 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 730 | 1,030 | 1,345 | 1,587 | 2,039 | 2,213 | 774 | 655 | 189 | 4 | 0 | 54 | 85 | |
| 581 | 817 | 1,082 | 1,281 | 1,655 | 2,044 | 847 | 648 | 208 | 24 | 7 | 56 | 86 | |
| Operating Profit | 149 | 213 | 262 | 307 | 384 | 169 | -73 | 7 | -19 | -20 | -7 | -2 | -2 |
| OPM % | 20% | 21% | 20% | 19% | 19% | 8% | -9% | 1.1% | -10% | -569% | -3.5% | -2.1% | |
| 8 | 21 | 13 | 6 | 11 | 26 | -211 | -677 | -56 | -92 | 47 | 13 | 15 | |
| Interest | 13 | 15 | 23 | 21 | 25 | 41 | 37 | 29 | 7 | 2 | 2 | 0 | 0 |
| Depreciation | 60 | 74 | 87 | 104 | 154 | 167 | 115 | 80 | 17 | 1 | 0 | 0 | 0 |
| Profit before tax | 85 | 145 | 165 | 188 | 216 | -13 | -437 | -779 | -99 | -116 | 37 | 11 | 13 |
| Tax % | 6% | 14% | 11% | 15% | 17% | -15% | 3% | 0% | 2% | 3% | 0% | 1% | |
| 80 | 125 | 146 | 160 | 178 | -11 | -450 | -782 | -100 | -120 | 37 | 11 | 13 | |
| EPS in Rs | 5.71 | 9.78 | 10.74 | 10.85 | 11.99 | -0.84 | -30.56 | -52.88 | -6.78 | -8.09 | 2.53 | 0.73 | 0.87 |
| Dividend Payout % | 17% | 10% | 9% | 15% | 8% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -26% |
| 5 Years: | -41% |
| 3 Years: | -34% |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -27% |
| 5 Years: | 15% |
| 3 Years: | 27% |
| TTM: | 80% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -22% |
| 5 Years: | -23% |
| 3 Years: | -16% |
| 1 Year: | 27% |
| Return on Equity | |
|---|---|
| 10 Years: | -10% |
| 5 Years: | -104% |
| 3 Years: | -47% |
| Last Year: | 17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 12 | 13 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
| Reserves | 512 | 619 | 898 | 1,314 | 1,504 | 1,561 | 1,110 | 166 | 94 | -24 | 6 | 16 |
| 209 | 336 | 237 | 323 | 474 | 553 | 514 | 59 | 46 | 37 | 0 | 0 | |
| 189 | 246 | 221 | 189 | 339 | 336 | 187 | 984 | 69 | 60 | 16 | 5 | |
| Total Liabilities | 922 | 1,214 | 1,369 | 1,840 | 2,331 | 2,465 | 1,826 | 1,223 | 224 | 88 | 36 | 36 |
| 359 | 543 | 554 | 589 | 1,091 | 1,234 | 934 | 101 | 73 | 30 | 0 | 0 | |
| CWIP | 17 | 3 | 21 | 42 | 41 | 1 | 0 | 3 | 11 | 0 | 0 | 0 |
| Investments | 6 | 21 | 10 | 59 | 10 | 18 | 7 | 0 | 0 | 0 | 0 | 0 |
| 541 | 647 | 785 | 1,150 | 1,188 | 1,213 | 885 | 1,119 | 140 | 58 | 36 | 36 | |
| Total Assets | 922 | 1,214 | 1,369 | 1,840 | 2,331 | 2,465 | 1,826 | 1,223 | 224 | 88 | 36 | 36 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 74 | 151 | 56 | 121 | 104 | 211 | 135 | 30 | 20 | 9 | -16 | -4 | |
| -14 | -292 | -130 | -179 | -474 | -233 | -57 | 15 | -3 | -7 | 22 | 2 | |
| -11 | 111 | 56 | 302 | 100 | 21 | -84 | -55 | -36 | -12 | -3 | -1 | |
| Net Cash Flow | 49 | -30 | -18 | 243 | -270 | -2 | -6 | -10 | -18 | -10 | 3 | -3 |
| Free Cash Flow | 46 | 35 | -30 | 39 | -23 | 54 | 133 | -2 | -12 | 2 | -16 | -4 |
| CFO/OP | 52% | 76% | 26% | 44% | 30% | 156% | -212% | 704% | -114% | -43% | 217% | 208% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 120 | 107 | 118 | 108 | 94 | 116 | 205 | 45 | 58 | 715 | 1 | |
| Inventory Days | 0 | |||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 120 | 107 | 118 | 108 | 94 | 116 | 205 | 45 | 58 | 715 | 1 | |
| Working Capital Days | 42 | 19 | 90 | 85 | 67 | 80 | 140 | 28 | -42 | -5,559 | 123 | |
| ROCE % | 13% | 16% | 17% | 15% | 13% | 1% | -9% | -6% | -14% | -22% | 11% | 19% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Life Sciences Revenue Share % |
|
|||||||||
| Total Employee Headcount count |
||||||||||
| Clinical Bed Capacity count |
||||||||||
| USA Revenue Share % |
||||||||||
| Order Book USD million |
||||||||||
| New Client Logos Added count |
||||||||||
Extracted by Screener AI
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Thursday, September 3, 2026
- Board approved director reappointment, statutory auditor appointment, and AGM on September 29, 2026.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday, September 1, 2026
- TAKE Limited appointed Tejas Nadkarni & Associates as internal auditor for FY 2025-26, effective September 1, 2026.
-
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
- Postal ballot approved Sunil Patra’s appointment as Managing Director on August 14, 2026.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper Advertisement of the Unaudited Financial Results for the quarter ended June 30, 2026.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
-
Annual Report 2011
from bse
Concalls
-
Aug 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Dec 2020TranscriptPPT
-
Sep 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Mar 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Aug 2018TranscriptPPT
-
May 2018TranscriptPPT
-
Feb 2018TranscriptPPT
-
Nov 2017TranscriptPPT
-
Nov 2017TranscriptPPT
-
Aug 2017TranscriptPPT
-
May 2017TranscriptPPT
-
Jan 2017TranscriptPPT
-
Dec 2016TranscriptPPT
-
Oct 2016TranscriptPPT
-
Feb 2016TranscriptAI SummaryPPT
Business Overview:[1]
Singapore-based TAKE Solutions Pte Limited holds a 52.90% stake in TSL, serving as the holding company. TSL specializes in Life Sciences and Supply Chain Management, providing comprehensive services in clinical development and specific offerings in supply chain. The company is involved in clinical trials, generics support, including bio-availability & bioequivalent studies, regulatory filing, and pharmacovigilance.